GSK and Bioventure Healthcare FZE sign a new agreement

GSK and Bioventure Healthcare FZE sign a new agreement

- Global science-led UK healthcare company GSK signed a new contract manufacturing agreement with Bioventure Healthcare FZE, a qualified UAE-based manufacturing facility, to transfer the secondary packaging of a range of its portfolio to the UAE.

- Agreement reinforces GSK’s commitment to advance patient health in the UAE, securing reliable supply of high-demand, widely prescribed essential medicines for patients in the country.

UAE: Global science-led UK healthcare company GlaxoSmithKline (GSK) has announced today a new manufacturing agreement with Bioventure Healthcare FZE (previously known as Geltec Healthcare FZE), a qualified UAE-based manufacturing facility. Through this venture, GSK will transfer to the UAE the secondary packaging of 20 of its key products across several therapy areas, including the central nervous system, dermatology, urology, allergy, and respiratory therapy areas.

This agreement will help to ensure a steady and seamless supply, enabling a more efficient response to address any emerging supply gaps. The move will also positively impact patients by ensuring that they are able to access GSK’s high-quality medicines prescribed by their doctors.

In alignment with GSK’s commitment to advance healthcare for patients in the UAE, the partnership will help in securing a reliable supply of high-demanded, widely prescribed essential medicines for patients in the country. It